Advertisement


Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Matthew Seymour, MD: A Clinical Trialist’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Advertisement